Breast

G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer

(Yahoo! Finance) June 18, 2019 - G1 Therapeutics, Inc. today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. Detailed data from this trial will be presented at a medical meeting later this year.

read article

PreludeDx Presents New Research in Luminal Stage 1 Breast Cancer Patients at the 2019 American Society of Clinical Oncology Annual Meeting

(Yahoo! Finance) June 18, 2019 - Prelude Corporation (PreludeDx) announced today its compelling data from research on stage 1 breast cancer patients presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

read article

Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel

(Yahoo! Finance) June 18, 2019 - Biocept, Inc. announces the commercial launch of its Target Selector™ NGS Breast Panel, the Company's multi-gene liquid biopsy panel specifically developed for breast cancer.

read article

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

(Amgen) June 13, 2019 - Amgen and Allergan plc today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "The FDA approval of KANJINTI is an important milestone for our biosimilars portfolio, providing an additional treatment option for patients across three types of cancer," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "KANJINTI is the third biosimilar from our portfolio to receive FDA approval, highlighting our long-term commitment to providing patients with serious illnesses access to high-quality biological therapies."

read corporate press release

Triple-Negative Breast Cancer among Black Women in the U.S. Varies by Birthplace

(ACS) June 13, 2019 - A new study finds substantial variation in the prevalence of triple-negative breast cancer among black women with breast cancer by birthplace in the United States.

read press release

Determining Risk Of Recurrence In Triple-Negative Breast Cancer

(HCI) June 12, 2019 - A personalized prognosis for patients diagnosed with triple-negative breast cancer was the goal of a new study at Huntsman Cancer Institute (HCI).

read article

Drug to Replace Chemotherapy May Reshape Cancer Care

(Bloomberg) June 11, 2019 - A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care. The complex biological medicines, called antibody drug conjugates (ADCs), have been in development for decades, and are now generating renewed excitement because of the success of one ADC in late-stage testing, a breast cancer treatment called DS-8201.

read article (free registration required)

Unhealthy Gut Promotes Spread of Breast Cancer, Study Finds

(UVA Health System) June 10, 2019 - An unhealthy, inflamed gut causes breast cancer to become much more invasive and spread more quickly to other parts of the body, new research from the UVA Cancer Center suggests.

read press release

Improving Breast Cancer Treatment

(Cardiff University [UK]) June 10, 2019 - Millions of patients with incurable breast cancer could benefit from Welsh-led research which shows it is possible to control the cancer for twice as long by combing an investigational therapy with standard treatment.

read article

Tart Cherry Shown To Decrease Joint Pain, Sore Muscles In Some Breast Cancer Patients

(MUSOM) June 10, 2019 - Tart cherry reduces the musculoskeletal effects of aromatase inhibitors in patients with non-metastatic breast cancer, according to new findings from a clinical trial by researchers at Marshall University Joan C. Edwards School of Medicine and Edwards Comprehensive Cancer Center.

read press release

LabCorp and QIAGEN Announce New therascreen PIK3CA Mutation Analysis Companion Diagnostic for Metastatic Breast Cancer

(LabCorp) June 7, 2019 - LabCorp®, a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new companion diagnostic called therascreen® PIK3CA PCR mutation analysis, which is now available through LabCorp and its Integrated Oncology specialty laboratory.

read corporate press release

I Face A Known Risk From Cancer And An Undetermined Risk From The Scan Used To Detect It. Which Is Worse?

(Washington Post) June 8, 2019 - With the FDA investigating the effects of MRI contrast agents, how many scans may be too many?

read article (free registration required)

Study Shows That In HER2 Positive Early Breast Cancer 6 Months Treatment With Herceptin Is As Good As 12 Months For Preventing Cancer Return

(University of Warwick [UK]) June 7, 2019 - Clinical trial results published in the Lancet today (6 June) show that women treated with 6 months of Herceptin for HER2 positive early breast cancer did as well in terms of their risk of breast cancer returning as those getting the currently conventional 12 months treatment.

read press release

Clinical Challenges: PARP Inhibitors and Metastatic Breast Ca

(MedPage Today) June 7, 2019 - Important new option for HER2-neg patients with a BRCA mutation, allowing further individualization of care.

read article (free registration required)

ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1

(Physician’s Weekly) June 5, 2019 - One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies.

read article

Amgen's Trastuzumab Biosimilar, Kanjinti, Clinically Similar to Herceptin in Cardiac Safety

(The Center For Biosimilars) June 6, 2019 - During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European Union under the name Kanjinti), versus the reference trastuzumab, Herceptin.

read article

AKT Inhibitor Doubles PFS in Advanced Breast Cancer

(MedPage Today) June 4, 2019 - Early randomized trial of capivasertib shows promise in ER-positive disease.

read article (free registration required)

Researchers Study Surveillance MRI in Breast Cancer Survivors

(RSNA) June 4, 2019 - The addition of breast MRI to mammography in screening breast cancer survivors for new cancers results in higher cancer detection rates, but also more biopsies that are benign, according to a large study published in the journal Radiology.

read press release

Many Breast Cancer Patients Unaware of Surgical Options to Reduce Scar Visibility

(Women & Infants) June 3, 2019 - The majority of women who underwent lumpectomy or mastectomy surgeries for breast cancer report that the scars from those surgeries negatively affect their daily lives.

read press release

Eisai Announces Additional Data from Ongoing Phase 1 Trial of Investigational Combination of HALAVEN® (eribulin mesylate) with Polyphor's CXCR4 Antagonist Balixafortide in HER2-Negative Metastatic Breast Cancer at ASCO 2019

(Markets Insider) June 4, 2019 - Eisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative metastatic breast cancer (Abstract #2606), were presented at the 2019 ASCO Annual Meeting in Chicago from May 31-June 4.

read article
Next Page